[1,2,4]triazolo[4,3-b]pyridazin-8-amine | 6583-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并哒嗪类
• 英文名称: [1,2,4]triazolo[4,3-b]pyridazin-8-amine
• CAS: 6583-39-7
• 化学式: C₅H₅N₅
• mdl: MFCD03085876
• 分子量: 135.128
• InChiKey: VQGGJIKNMDSGEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [1,2,4]triazolo[4,3-b]pyridazin-8-amine 在 二碘甲烷 、 potassium carbonate 、 亚硝酸异戊酯 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 17.0h， 生成 [2-(4-methoxy-phenyl)-ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-8-yl-amine
  参考文献：
  名称：

  Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3-b]pyridazin-8-amine Derivatives as Tankyrase Inhibitors

  摘要：

  Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.

  DOI：

  10.1021/jm401356t
• 作为产物：
  描述：

  6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 [1,2,4]triazolo[4,3-b]pyridazin-8-amine
  参考文献：
  名称：

  [EN] COMPOUNDS AS CASEIN KINASE INHIBITORS
  [FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA CASÉINE KINASE

  摘要：

  本文提供酪蛋白激酶抑制剂或其药学上可接受的盐。同时还提供相应的组合物、治疗方法和中间体。

  公开号：

  WO2022127755A1

文献信息

• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020097609A1

  公开（公告）日：2020-05-14

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的失调的方法。这些化合物具有Formula（X）的结构或其在药学上可接受的异构体，消旋体，水合物，溶剂合物，同位素或盐，其中R1，R2，R3，R4，R9，R10，R11和R12，Q5，Q6，Q7和Q8如本文所定义。
• [EN] COMPOUNDS AS CASEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA CASÉINE KINASE
  申请人：GRITSCIENCE BIOPHARMACEUTICALS CO LTD

  公开号：WO2022127755A1

  公开（公告）日：2022-06-23

  Provided herein are casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding compositions, methods of treatment, and intermediates are also provided.

  本文提供酪蛋白激酶抑制剂或其药学上可接受的盐。同时还提供相应的组合物、治疗方法和中间体。
• Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3-<i>b</i>]pyridazin-8-amine Derivatives as Tankyrase Inhibitors
  作者：Paride Liscio、Andrea Carotti、Stefania Asciutti、Tobias Karlberg、Daniele Bellocchi、Laura Llacuna、Antonio Macchiarulo、Stuart A Aaronson、Herwig Schüler、Roberto Pellicciari、Emidio Camaioni

  DOI：10.1021/jm401356t

  日期：2014.3.27

  Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.